DA
IOVA icon

Duality Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Duality Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-44,367
Closed -$202K – 653
2023
Q3 		$202K Buy
44,367
+19,946
+82% +$130K 0.02% 527
2023
Q2 		$172K Sell
24,421
-157,317
-87% -$1.13M 0.02% 493
2023
Q1 		$1.11M Buy
181,738
+16,780
+10% +$116K 0.13% 285
2022
Q4 		$1.05M Buy
164,958
+57,017
+53% +$445K 0.12% 303
2022
Q3 		$1.03M Sell
107,941
-15,626
-13% -$180K 0.11% 304
2022
Q2 		$1.36M Buy
+123,567
New +$1.62M 0.13% 289

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Duality Advisers's IOVA Position: Q4 2023 in Review

Duality Advisers sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 44,367 shares — an estimated $202K sold.

Duality Advisers first reported a position in IOVA in Q2 2022 and held it in 6 quarters. The position peaked at $1.36M in Q2 2022. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • Duality Advisers reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Duality Advisers sold 44,367 Iovance Biotherapeutics shares in Q4 2023, an estimated $202K.
  • Duality Advisers first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • Duality Advisers's Iovance Biotherapeutics position peaked at $1.36M in Q2 2022.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Duality Advisers's 13F filing for Q4 2023, filed 1 Feb 2024.